While a few preclinical studies show the efficacy of PCSK9 inhibition in attenuating cell proliferation and survival of ovarian cancer cells [68], the clinical impact of anti-PCSK9 agents is yet to be explored in OC. Here, PCSK9 is linked to ovarian carcinoma.